Two Sigma Investments, LP Rhythm Pharmaceuticals, Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.62 - $13.9 $192,277 - $310,053	-22,306 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.68 - $20.72 $406,136 - $720,475	-34,772 Reduced 60.92%	22,306 $291,000
Q2 2021 Aug 16, 2021	SELL	$18.52 - $22.55 $4.4 Million - $5.36 Million	-237,582 Reduced 80.63%	57,078 $1.12 Million
Q1 2021 May 17, 2021	BUY	$20.25 - $39.49 $5.49 Million - $10.7 Million	270,979 Added 1144.29%	294,660 $6.27 Million
Q4 2020 Feb 16, 2021	BUY	$21.17 - $32.61 $41,048 - $63,230	1,939 Added 8.92%	23,681 $704,000
Q3 2020 Nov 16, 2020	BUY	$18.13 - $30.61 $394,182 - $665,522	21,742 New	21,742 $471,000
Q1 2020 May 15, 2020	SELL	$13.16 - $22.9 $551,693 - $960,013	-41,922 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$19.53 - $25.5 $818,736 - $1.07 Million	41,922 New	41,922 $963,000
Q3 2019 Nov 14, 2019	SELL	$18.62 - $24.51 $214,130 - $281,865	-11,500 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$21.11 - $28.48 $55,498 - $74,873	-2,629 Reduced 18.61%	11,500 $253,000
Q1 2019 May 15, 2019	BUY	$24.76 - $31.66 $349,834 - $447,324	14,129 New	14,129 $387,000

213

64.4M

445K

26.6K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.21B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.